The company received European Commission approval to expand the label for its CAR-T cell therapy, Breyanzi, for patients with relapsed or refractory Mantle Cell Lymphoma. This adds to its growing roster of European CAR-T indications. The stock also received a positive boost from a rival's unexpectedly strong report on a blood thinner. Despite a recent share price rebound of nearly 9%, the stock remains below its yearly highs, and total shareholders are still down nearly 15% for the year.